These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 38054558)

  • 1. Chimeric antigen receptor and bispecific T-cell engager therapies in multiple myeloma patients with prior allogeneic transplantation.
    Hammons L; Haider S; Portuguese AJ; Banerjee R; Szabo A; Pasquini M; Chhabra S; Radhakrishnan S; Mohan M; Narra R; Dong J; Janz S; Shah NN; Hamadani M; D'Souza A; Hari P; Dhakal B
    Br J Haematol; 2024 Mar; 204(3):887-891. PubMed ID: 38054558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Treatment Modality and Route of Administration on Cytokine Release Syndrome in Relapsed or Refractory Multiple Myeloma: A Meta-Analysis.
    Soltantabar P; Sharma S; Wang D; Lon HK; Czibere A; Hickmann A; Elmeliegy M
    Clin Pharmacol Ther; 2024 Jun; 115(6):1258-1268. PubMed ID: 38459622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy.
    Chen W; Ma Y; Shen Z; Chen H; Ma R; Yan D; Shi M; Wang X; Song X; Sun C; Cao J; Cheng H; Zhu F; Sun H; Li D; Li Z; Zheng J; Xu K; Sang W
    Front Immunol; 2021; 12():755549. PubMed ID: 34777367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma.
    Qu X; An G; Sui W; Wang T; Zhang X; Yang J; Zhang Y; Zhang L; Zhu D; Huang J; Zhu S; Yao X; Li J; Zheng C; Zhu K; Wei Y; Lv X; Lan L; Yao Y; Zhou D; Lu P; Qiu L; Li J
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36100310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bispecific Antibodies in the Treatment of Multiple Myeloma.
    Zhou X; Xiao X; Kortuem KM; Einsele H
    Hematol Oncol Clin North Am; 2024 Apr; 38(2):361-381. PubMed ID: 38199897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Toxicity of CD19 Chimeric Antigen Receptor T Cell Therapy for Lymphoma in Solid Organ Transplant Recipients: A Systematic Review and Meta-Analysis.
    Yamshon S; Gribbin C; Chen Z; Demetres M; Pasciolla M; Alhomoud M; Martin P; Shore T
    Transplant Cell Ther; 2024 Jan; 30(1):73.e1-73.e12. PubMed ID: 37279856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma.
    Banerjee R; Marsal J; Huang CY; Lo M; Kambhampati S; Kennedy VE; Arora S; Wolf JL; Martin TG; Wong SW; Shah N
    Transplant Cell Ther; 2021 Jun; 27(6):477.e1-477.e7. PubMed ID: 33831353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapy in Multiple Myeloma: Moving Into the Future.
    Holstein SA; Grant SJ; Wildes TM
    J Clin Oncol; 2023 Sep; 41(27):4416-4429. PubMed ID: 37471687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Practical Aspects of Immunotherapy: A Report from the 20th International Myeloma Society (IMS) Annual Meeting.
    Raje NS; Cohen AD; Patel KK; van de Donk NWCJ; Richter J; San-Miguel J
    Clin Lymphoma Myeloma Leuk; 2024 Jun; 24(6):350-357. PubMed ID: 38627181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrating CAR T-Cell Therapy and Transplantation: Comparisons of Safety and Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation After CAR T-Cell or Chemotherapy-Based Complete Remission in B-Cell Acute Lymphoblastic Leukemia.
    Zhao YL; Liu DY; Sun RJ; Zhang JP; Zhou JR; Wei ZJ; Xiong M; Cao XY; Lu Y; Yang JF; Zhang X; Lu DP; Lu P
    Front Immunol; 2021; 12():605766. PubMed ID: 34025637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric Antigen Receptor T Cell Therapy for Myeloma: Where Are We Now and What Is Needed to Move Chimeric Antigen Receptor T Cells Forward to Earlier Lines of Therapy? Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.
    Anderson LD; Dhakal B; Jain T; Oluwole OO; Shah GL; Sidana S; Perales MA; Pasquini MC
    Transplant Cell Ther; 2024 Jan; 30(1):17-37. PubMed ID: 37913909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of glucocorticoids on short-term and long-term outcomes in patients with relapsed/refractory multiple myeloma treated with CAR-T therapy.
    Wang X; Qi Y; Li H; Liu F; Cao J; Chen W; Wang Y; Qi K; Yan Z; Zhu F; Li Z; Cheng H; Xu K
    Front Immunol; 2022; 13():943004. PubMed ID: 36081517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel)¬†for triple-class exposed relapsed/refractory multiple myeloma patients.
    Sanoyan DA; Seipel K; Bacher U; Kronig MN; Porret N; Wiedemann G; Daskalakis M; Pabst T
    BMC Cancer; 2023 Apr; 23(1):345. PubMed ID: 37061680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of CAR-Modified T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma: A Meta-Analysis of Prospective Clinical Trials.
    Xiang X; He Q; Ou Y; Wang W; Wu Y
    Front Pharmacol; 2020; 11():544754. PubMed ID: 33343342
    [No Abstract]   [Full Text] [Related]  

  • 15. Impact of Frailty on Outcomes after Chimeric Antigen Receptor T Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma.
    Davis JA; Dima D; Ahmed N; DeJarnette S; McGuirk J; Jia X; Raza S; Khouri J; Valent J; Anwer F; Abdallah AO; Hashmi H
    Transplant Cell Ther; 2024 Mar; 30(3):298-305. PubMed ID: 38142943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma.
    Mei H; Li C; Jiang H; Zhao X; Huang Z; Jin D; Guo T; Kou H; Liu L; Tang L; Yin P; Wang Z; Ai L; Ke S; Xia Y; Deng J; Chen L; Cai L; Sun C; Xia L; Hua G; Hu Y
    J Hematol Oncol; 2021 Oct; 14(1):161. PubMed ID: 34627333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials.
    Que Y; Xu M; Xu Y; Almeida VDF; Zhu L; Wang Z; Wang Y; Liu X; Jiang L; Wang D; Li C; Zhou J
    Front Immunol; 2021; 12():755866. PubMed ID: 34777368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of infectious complications with BCMA-directed therapies in multiple myeloma.
    Nath K; Shekarkhand T; Nemirovsky D; Derkach A; Costa BA; Nishimura N; Farzana T; Rueda C; Chung DJ; Landau HJ; Lahoud OB; Scordo M; Shah GL; Hassoun H; Maclachlan K; Korde N; Shah UA; Tan CR; Hultcrantz M; Giralt SA; Usmani SZ; Shahid Z; Mailankody S; Lesokhin AM
    Blood Cancer J; 2024 May; 14(1):88. PubMed ID: 38821925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy.
    An L; Lin Y; Deng B; Yin Z; Zhao D; Ling Z; Wu T; Zhao Y; Chang AH; Tong C; Liu S
    BMC Cancer; 2022 Apr; 22(1):393. PubMed ID: 35410148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Allogeneic donor-derived CD19 CAR-T therapy of relapsed B-cell acute lmphoblastic leukemia after allogeneic hematopoietic stem cell transplantation].
    Ma RZ; He Y; Yang DL; Wei JL; Pang AM; Jiang EL; Wang JX; Han MZ; Zhang RL; Feng SZ
    Zhonghua Xue Ye Xue Za Zhi; 2021 May; 42(5):383-389. PubMed ID: 34218580
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.